IL262124A - T cell receptors - Google Patents

T cell receptors

Info

Publication number
IL262124A
IL262124A IL262124A IL26212418A IL262124A IL 262124 A IL262124 A IL 262124A IL 262124 A IL262124 A IL 262124A IL 26212418 A IL26212418 A IL 26212418A IL 262124 A IL262124 A IL 262124A
Authority
IL
Israel
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
IL262124A
Other languages
Hebrew (he)
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58536983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL262124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of IL262124A publication Critical patent/IL262124A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
IL262124A 2016-04-08 2018-10-04 T cell receptors IL262124A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606156 2016-04-08
PCT/EP2017/058578 WO2017174823A1 (en) 2016-04-08 2017-04-10 T cell receptors

Publications (1)

Publication Number Publication Date
IL262124A true IL262124A (en) 2018-11-29

Family

ID=58536983

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262124A IL262124A (en) 2016-04-08 2018-10-04 T cell receptors

Country Status (15)

Country Link
US (3) US20190144521A1 (en)
EP (2) EP3925972A1 (en)
JP (2) JP7204484B2 (en)
KR (1) KR20190065189A (en)
CN (2) CN109476724B (en)
AU (2) AU2017248121B2 (en)
BR (1) BR112018070637A2 (en)
CA (1) CA3020555A1 (en)
ES (1) ES2788188T5 (en)
IL (1) IL262124A (en)
MX (1) MX2018012268A (en)
RU (1) RU2018138837A (en)
SG (1) SG11201808750PA (en)
WO (1) WO2017174823A1 (en)
ZA (1) ZA201806862B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057014T2 (en) 2014-12-23 2022-04-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
CA3020530A1 (en) * 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
PL3440106T3 (en) 2016-04-08 2022-01-31 Adaptimmune Limited T cell receptors
BR112018070637A2 (en) 2016-04-08 2019-02-05 Adaptimmune Ltd t cell receptors
AU2018346719A1 (en) 2017-10-06 2020-04-23 Oslo Universitetssykehus Hf Chimeric antigen receptors
JPWO2019151392A1 (en) * 2018-01-31 2021-02-04 国立大学法人東北大学 Antigen-specific MHC expression regulation method
US20210363215A1 (en) * 2018-04-19 2021-11-25 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
CN110172091B (en) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof
WO2020257288A2 (en) * 2019-06-18 2020-12-24 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021028690A1 (en) 2019-08-13 2021-02-18 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
US20210048442A1 (en) 2019-08-13 2021-02-18 Immatics Biotechnologies Gmbh Method for the characterization of peptide:mhc binding polypeptides
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
CN111647069B (en) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 Improved TCR and application thereof
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
JP2024502235A (en) * 2020-12-22 2024-01-18 アムジエン・インコーポレーテツド MAGE-B2 specific T cell receptor
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
TW202313094A (en) 2021-05-18 2023-04-01 美商基利科學股份有限公司 Methods of using flt3l-fc fusion proteins
TW202330504A (en) 2021-10-28 2023-08-01 美商基利科學股份有限公司 Pyridizin-3(2h)-one derivatives
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN116836261A (en) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 High-affinity TCR (TCR) for recognizing MAGE-A4 antigen, and sequence and application thereof
TW202400138A (en) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Kras g12d modulating compounds
CN117106060A (en) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 High-affinity T cell receptor for recognizing MAGE and application thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
EP1117679B9 (en) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
ATE290020T1 (en) 2001-08-31 2005-03-15 Avidex Ltd SOLUBLE T CELL RECEPTOR
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
PL2440575T3 (en) 2009-06-09 2015-04-30 Vaxon Biotech Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy
ME02810B (en) 2010-09-20 2018-01-20 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
BR112014008691A2 (en) * 2011-10-14 2017-06-13 Teva Pharmaceuticals Australia Pty Ltd antibodies to cd1d
EA035475B1 (en) * 2013-06-10 2020-06-23 Дана-Фарбер Кэнсер Инститьют, Инк. Methods and compositions for reducing immunosupression by tumor cells
JP6255360B2 (en) 2015-03-04 2017-12-27 ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ Identification, optimization and use of immunotherapy for shared HLA-B * 0702 epitopes
MD3440105T2 (en) 2016-04-08 2022-09-30 Immunocore Ltd T cell receptors
PL3440106T3 (en) 2016-04-08 2022-01-31 Adaptimmune Limited T cell receptors
CA3020530A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
BR112018070637A2 (en) 2016-04-08 2019-02-05 Adaptimmune Ltd t cell receptors

Also Published As

Publication number Publication date
US20240010702A1 (en) 2024-01-11
AU2017248121B2 (en) 2022-07-21
JP2019516356A (en) 2019-06-20
AU2017248121A1 (en) 2018-11-22
SG11201808750PA (en) 2018-11-29
WO2017174823A1 (en) 2017-10-12
ES2788188T5 (en) 2023-10-24
CN109476724B (en) 2023-04-04
KR20190065189A (en) 2019-06-11
CN109476724A (en) 2019-03-15
WO2017174823A4 (en) 2017-12-07
AU2022256182A1 (en) 2022-11-24
JP7204484B2 (en) 2023-01-16
CN116239669A (en) 2023-06-09
ES2788188T3 (en) 2020-10-20
MX2018012268A (en) 2019-02-07
BR112018070637A2 (en) 2019-02-05
RU2018138837A3 (en) 2020-07-30
RU2018138837A (en) 2020-05-12
ZA201806862B (en) 2021-04-28
US20190144521A1 (en) 2019-05-16
EP3925972A1 (en) 2021-12-22
EP3440104B1 (en) 2020-03-11
EP3440104A1 (en) 2019-02-13
EP3440104B2 (en) 2023-06-14
CA3020555A1 (en) 2017-10-12
US11753456B2 (en) 2023-09-12
JP2022122913A (en) 2022-08-23
US20220025013A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
IL262144A (en) T cell receptors
ZA201806862B (en) T cell receptors
ZA201806866B (en) T cell receptors
IL271435A (en) T cell receptors
ZA201806865B (en) T cell receptors
IL264425B1 (en) Anti-kras-g12d t cell receptors
IL251524B (en) T cell receptors
GB201522592D0 (en) T cell receptors
RS64952B1 (en) T cell receptors
GB201518991D0 (en) T cell receptors